Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety
INTRODUCTION: Histone deacetylases (HDACs) represent one of the most validated cancer targets. The inhibition of HDACs has been proven to be a successful strategy for the development of novel anticancer candidates. METHODS: This work describes design and synthesis of a new set of HDAC inhibitors ( 7A-C and 8A, B) utilizing ligustrazine as a novel cap moiety, and achieving the ... Read more